These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1617 related items for PubMed ID: 16977574

  • 21. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease: the PRO. WILL Study.
    Federici AB.
    Haemophilia; 2007 Dec; 13 Suppl 5():15-24. PubMed ID: 18078393
    [Abstract] [Full Text] [Related]

  • 22. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G, Kreuz W.
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.
    Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, Bucciarelli P.
    Thromb Haemost; 1999 Jul; 82(1):35-9. PubMed ID: 10456451
    [Abstract] [Full Text] [Related]

  • 24. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [Abstract] [Full Text] [Related]

  • 25. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
    Favaloro EJ, Thom J, Patterson D, Just S, Baccala M, Dixon T, Meiring M, Koutts J, Rowell J, Baker R.
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):475-83. PubMed ID: 19584715
    [Abstract] [Full Text] [Related]

  • 26. Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience.
    Akin M, Kavakli K.
    Semin Thromb Hemost; 2011 Jul; 37(5):581-6. PubMed ID: 22102203
    [Abstract] [Full Text] [Related]

  • 27. Von Willebrand's disease: clinical management.
    Federici AB, Castaman G, Thompson A, Berntorp E.
    Haemophilia; 2006 Jul; 12 Suppl 3():152-8. PubMed ID: 16684011
    [Abstract] [Full Text] [Related]

  • 28. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G, Federici AB, Bernardi M, Moroni B, Bertoncello K, Rodeghiero F.
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [Abstract] [Full Text] [Related]

  • 29. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G, Federici AB, Rodeghiero F, Mannucci PM.
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [Abstract] [Full Text] [Related]

  • 30. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A.
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [Abstract] [Full Text] [Related]

  • 31. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S, Mezzasoma AM, Leone M, Gresele P.
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [Abstract] [Full Text] [Related]

  • 32. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
    César JM, Avello AG, Vecino A, Cerveró C, Laraña JG, Fuertes IF, Villarrubia J, López J, de Oteyza JP, Velasco JL, Cantalapiedra A, Herrera P, Herrero S, Navarro JL.
    Med Clin (Barc); 1998 Nov 14; 111(16):601-3. PubMed ID: 9881332
    [Abstract] [Full Text] [Related]

  • 33. A comparative in vitro evaluation of six von Willebrand factor concentrates.
    Lethagen S, Carlson M, Hillarp A.
    Haemophilia; 2004 May 14; 10(3):243-9. PubMed ID: 15086321
    [Abstract] [Full Text] [Related]

  • 34. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ, van Vliet HH.
    Acta Haematol; 2009 May 14; 121(2-3):154-66. PubMed ID: 19506362
    [Abstract] [Full Text] [Related]

  • 35. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R.
    Haemophilia; 2008 Sep 14; 14(5):963-7. PubMed ID: 18624696
    [Abstract] [Full Text] [Related]

  • 36. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.
    Blood Coagul Fibrinolysis; 2004 Jun 14; 15(4):323-30. PubMed ID: 15166918
    [Abstract] [Full Text] [Related]

  • 37. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.
    Haemophilia; 2010 Jul 01; 16(4):615-24. PubMed ID: 20331755
    [Abstract] [Full Text] [Related]

  • 38. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB.
    Haematologica; 2003 Jun 01; 88(6):EREP02. PubMed ID: 12826528
    [Abstract] [Full Text] [Related]

  • 39. Epidemiology, diagnosis, and management of von Willebrand disease in India.
    Ghosh K, Shetty S.
    Semin Thromb Hemost; 2011 Jul 01; 37(5):595-601. PubMed ID: 22102205
    [Abstract] [Full Text] [Related]

  • 40. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
    Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM.
    J Thromb Haemost; 2007 Jun 01; 5(6):1115-24. PubMed ID: 17403090
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 81.